MYLOTARG™ | Pfizer
网页Pfizer Oncology Together™ provides financial assistance resources to help patients access their prescribed Oncology medicines. MYLOTARG - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources. for Healthcare professionals:
FDA approves Mylotarg for treatment of acute myeloid leukemia
网页The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33...
Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab …
网页2017年9月1日 — Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.1 MYLOTARG is the first …
Mylotarg: Uses, Dosage, Side Effects & Warnings - Drugs.com
网页2024年3月19日 — Mylotarg is a monoclonal antibody linked to a chemotherapy drug. Monoclonal antibodies are made to target and destroy only certain cells in the body. This …
MYLOTARG™ (gemtuzumab ozogamicin) | Pfizer Medical …
网页MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
Gemtuzumab ozogamicin for acute myeloid leukemia
网页2017年11月30日 — High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients
FDA Approval Summary: Mylotarg for Treatment of Patients with …
网页On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R/R) CD33-positive acute myeloid leukemia (AML) in patients 2 years of age and older.
MYLOTARG™ Indications and Usage - Pfizer Medical Information
网页MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older. Find MYLOTARG™ medical information: Our scientific content is evidence-based, scientifically balanced and non-promotional.
FDA Approves Gemtuzumab Ozogamicin for CD33-positive …
网页On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML)...
MYLOTARG™ Highlights - Pfizer Medical Information
网页MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older (1.1). treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older (1.2). DOSAGE AND …
- 某些结果已被删除一些您可能无法访问的结果已被隐去。显示无法访问的结果
跳至内容